This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1993 Jul;19(3):197-228.

doi: 10.1016/0305-7372(93)90036-q.

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

A P Launchbury¹, N Habboubi

Affiliations

PMID: 8334677
DOI: 10.1016/0305-7372(93)90036-q

Review

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

A P Launchbury et al. Cancer Treat Rev. 1993 Jul.

. 1993 Jul;19(3):197-228.

doi: 10.1016/0305-7372(93)90036-q.

Authors

A P Launchbury¹, N Habboubi

Affiliation

¹ Farmitalia Carlo Erba Ltd, St Albans, UK.

PMID: 8334677
DOI: 10.1016/0305-7372(93)90036-q

No abstract available

PubMed Disclaimer

Similar articles

Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ. Ventura GJ. J Clin Oncol. 2005 Apr 20;23(12):2873; author reply 2873-4. doi: 10.1200/JCO.2005.05.332. J Clin Oncol. 2005. PMID: 15838014 No abstract available.
Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
Eto H, Oka Y, Ueno K, Nakamura I, Yoshimura K, Arakawa S, Kamidono S, Obe S, Ogawa T, Hamami G, et al. Eto H, et al. Cancer Chemother Pharmacol. 1994;35 Suppl:S46-51. doi: 10.1007/BF00686919. Cancer Chemother Pharmacol. 1994. PMID: 7994786 Clinical Trial.
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L, Bramwell V, Moran LA. Seymour L, et al. Cancer Prev Control. 1999 Apr;3(2):145-59. Cancer Prev Control. 1999. PMID: 10474762
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
Anderström C. Anderström C. Cancer Chemother Pharmacol. 1994;35 Suppl:S97-100. doi: 10.1007/BF00686930. Cancer Chemother Pharmacol. 1994. PMID: 7994797 Review.
Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M, Bell R, Dang C. Khasraw M, et al. Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Breast. 2012. PMID: 22260846 Review.

See all similar articles

Cited by

Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.
Marcelo GA, Galhano J, Robalo TT, Cruz MM, Marcos MD, Martínez-Máñez R, Duarte MP, Capelo-Martínez JL, Lodeiro C, Oliveira E. Marcelo GA, et al. Int J Mol Sci. 2022 Oct 14;23(20):12287. doi: 10.3390/ijms232012287. Int J Mol Sci. 2022. PMID: 36293142 Free PMC article.
Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
Avilés A, Nambo MJ, Neri N, Cleto S, Castañeda C, Huerta-Guzmàn J, Murillo E, Contreras M, Talavera A, González M. Avilés A, et al. Med Oncol. 2007;24(1):85-9. doi: 10.1007/BF02685907. Med Oncol. 2007. PMID: 17673816 Clinical Trial.
The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial.
Liu D, Wu J, Lin C, Ding S, Lu S, Fang Y, Huang J, Hong J, Gao W, Zhu S, Chen X, Huang O, He J, Chen W, Li Y, Shen K, Zhu L. Liu D, et al. Cancers (Basel). 2022 Jun 30;14(13):3221. doi: 10.3390/cancers14133221. Cancers (Basel). 2022. PMID: 35804991 Free PMC article.
Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.
Ressing M, Becker C, Müller C, Mahmoudpour SH, Calaminus G, Langer T, Erdmann F, Voigt M, Kaiser M, Kaatsch P, Blettner M, Spix C. Ressing M, et al. Cancer Rep (Hoboken). 2023 May;6(5):e1811. doi: 10.1002/cnr2.1811. Epub 2023 Mar 28. Cancer Rep (Hoboken). 2023. PMID: 36975206 Free PMC article. Review.
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A, Tonelli P. Neri B, et al. Br J Cancer. 2007 Apr 10;96(7):1043-6. doi: 10.1038/sj.bjc.6603644. Epub 2007 Mar 13. Br J Cancer. 2007. PMID: 17353926 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database